News

CEQUA, which offers the highest concentration of cyclosporine for ophthalmic use approved by the U.S. Food and Drug Administration (FDA), is indicated to increase tear production in patients

Reyvow is a new oral medication for the acute treatment of migraine, with or without aura, in adults. It binds to 5-HT1F receptors with high affinity. Reyvow is

“We are encouraged by the durability of both the efficacy and safety profiles of filgotinib seen in these studies,” said John Sundy, MD, PhD, Senior Vice President, Inflammation

Under the deal, Ra Pharmaceuticals shareholders will secure $48 in cash for each of its share at closing. Based in Cambridge of Massachusetts, Ra Pharma uses an advanced

Currently being evaluated in a Phase 3 study in people with primary mitochondrial myopathy (PMM) – a genetic mitochondrial disease – elamipretide is a novel, potential first-in-class therapy

IONIS-FXI-LRx utilizes Ionis’ advanced LIgand Conjugated Antisense (LICA) technology platform and is designed to reduce the production of Factor XI (FXI), a clotting factor produced in the liver.

Inebilizumab will be developed and marketed in the Asian regions for the treatment of neuromyelitis optica spectrum disorder (NMOSD), and also other potential indications in the future. As

Lebrikizumab is a novel, investigational, monoclonal antibody designed to bind IL-13 with very high affinity, specifically preventing the formation of the IL-13Rα1/IL-4Rα heterodimer complex and subsequent signaling, thereby

The acquisition of Amarex will help NSF to expand its consulting services to the medical device and pharma/biotech industries. Amarex will be included in NSF’s global health science